| Summary: | 碩士 === 國立中興大學 === 環境工程學系所 === 106 === The aims of this study were to investigate whether the background levels of 17-estradiol-2(E2)-derived quinone protein adducts in human Albumin (Alb) associate with indicaters of diagnosis and treatment for breast cancer, including stage, progesterone receptor (PR)、estrogen receptor (ER)、 human epidermal growth factor receptor 2, HER2) in Taiwanese women (n=143). Results from the analysis indicated that levels of Alb adducts of estrogen quinones, including E2-2,3-Q-4-S-Alb and E2-3,4-Q-2-S-Alb were detected in all subjects (n=75) with mean (standard deviation) levels at 399(257) and 676(337) pmole/g pmole/g, respectively. No significant difference of these adducts was observed as distinguished by stage of breast cancer. In addition, levels of E2-2,3-Q-4-S-Alb and E2-3,4-Q-2-S-Alb were comparable with those detected in patients with benign tumor women 472(188) and 818(280) pmole/g, respectively). However, these adduct were about 1.4 fold greater than those in healthy controls 294(116) and 138(57) pmole/g, respectively) (p<0.001).
Further investigation into the association of these adducts with indicators of diagnosis and treatment for breast cancer, including ER(+)/(-)、PR(+)/(-)、HER2 (+)/(-), indicated that levels of E2-2,3-Q-4-S-Alb and E2-3,4-Q-2-S-Alb did not correlate with the status of these indicators. However, as distinguished by mean values of E2-2,3-Q-4-S-Alb and E2-3,4-Q-2-S-Alb, levels of E2-2,3-Q-4-S-Alb were about 27% greater in PR(+) patients than those with PR(-) among subjects with adduct levels less than or equal to the mean values (p<0.001). Similarly, levels of E2-2,3-Q-4-S-Alb were about 9% greater in HER2(-) patients than those patients with Her 2(+) (p<0.05). Overall this evidence suggests that Albumin quinone protein adducts biomarkers of breast cancer in preventive medicine associates with indicators of Screening for breast cancer.
|
|---|
